flupentixol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1211 2709-56-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • flupentixol hydrochloride
  • flupenthixol
  • fluanxol
  • flupentixol
  • fluxanxol
  • flupentixol dihydrochloride
  • N-7009
  • flupentixol HCl
A thioxanthene neuroleptic that, unlike CHLORPROMAZINE, is claimed to have CNS-activating properties. It is used in the treatment of psychoses although not in excited or manic patients. (From Martindale, The Extra Pharmacopoeia, 30th ed, p595)
  • Molecular weight: 434.52
  • Formula: C23H25F3N2OS
  • CLOGP: 4.34
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 26.71
  • ALOGS: -5.04
  • ROTB: 6

Drug dosage:

DoseUnitRoute
6 mg O
4 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.10 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance) 4.14 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 34.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1964 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anosognosia 918.68 113.59 151 2795 2083 50600095
Blood prolactin abnormal 915.59 113.59 150 2796 2025 50600153
Disturbance in social behaviour 872.79 113.59 150 2796 2744 50599434
Sexual dysfunction 853.48 113.59 150 2796 3142 50599036
Metabolic disorder 782.55 113.59 150 2796 5136 50597042
Personality change 754.22 113.59 147 2799 5498 50596680
Dystonia 606.96 113.59 140 2806 11786 50590392
Dyskinesia 557.46 113.59 155 2791 27706 50574472
Sedation 552.08 113.59 157 2789 30453 50571725
Suicide attempt 503.13 113.59 165 2781 51567 50550611
Blood glucose increased 403.17 113.59 152 2794 71172 50531006
Insurance issue 206.95 113.59 44 2902 2504 50599674
Condition aggravated 135.54 113.59 122 2824 296936 50305242
Drug ineffective 123.86 113.59 190 2756 819143 49783035
Adverse drug reaction 119.36 113.59 60 2886 55162 50547016

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapeutic product effect variable 321.04 113.85 63 2209 1814 29570441
Antipsychotic drug level below therapeutic 317.88 113.85 63 2209 1911 29570344
Disinhibition 300.40 113.85 63 2209 2544 29569711
Akathisia 299.91 113.85 75 2197 6667 29565588
Suicide attempt 298.74 113.85 108 2164 34002 29538253
Obsessive-compulsive disorder 296.69 113.85 69 2203 4507 29567748
Euphoric mood 261.78 113.85 63 2209 4762 29567493
Increased appetite 257.38 113.85 65 2207 5999 29566256
Anosognosia 199.35 113.85 37 2235 781 29571474
Blood prolactin abnormal 197.50 113.85 37 2235 823 29571432
Disturbance in social behaviour 172.31 113.85 37 2235 1665 29570590
Metabolic disorder 143.78 113.85 37 2235 3658 29568597
Sexual dysfunction 136.09 113.85 39 2233 5775 29566480
Therapeutic product effect incomplete 135.29 113.85 64 2208 39241 29533014
Weight increased 127.95 113.85 77 2195 76590 29495665
Leukopenia 123.03 113.85 67 2205 55136 29517119
Dystonia 120.21 113.85 40 2232 9709 29562546
Personality change 117.03 113.85 33 2239 4605 29567650
Dyslipidaemia 116.92 113.85 35 2237 6026 29566229

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anosognosia 1043.16 78.92 177 4044 2628 64491883
Blood prolactin abnormal 1040.89 78.92 176 4045 2556 64491955
Disturbance in social behaviour 978.90 78.92 176 4045 3711 64490800
Sexual dysfunction 901.52 78.92 178 4043 6293 64488218
Metabolic disorder 858.90 78.92 176 4045 7521 64486990
Personality change 816.47 78.92 172 4049 8421 64486090
Dystonia 662.00 78.92 168 4053 18697 64475814
Dyskinesia 633.83 78.92 190 4031 39198 64455313
Suicide attempt 623.28 78.92 216 4005 70791 64423720
Sedation 611.35 78.92 187 4034 41275 64453236
Blood glucose increased 426.76 78.92 179 4042 97894 64396617
Insurance issue 208.19 78.92 46 4175 2780 64491731
Drug ineffective 183.54 78.92 247 3974 840000 63654511
Condition aggravated 163.85 78.92 158 4063 372268 64122243
Adverse drug reaction 132.73 78.92 63 4158 45401 64449110
Akathisia 88.84 78.92 32 4189 11478 64483033

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AF01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Thioxanthene derivatives
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:37890 alpha-adrenergic receptor blockaders
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:65190 typical antipsychotic drugs
CHEBI has role CHEBI:76779 post-proline endopeptidase inhibitors
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Schizophrenia indication 58214004 DOID:5419




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.19 Basic
pKa2 4.19 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(1A) dopamine receptor GPCR ANTAGONIST Ki 8.40 IUPHAR IUPHAR
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.82 IUPHAR IUPHAR
Sigma non-opioid intracellular receptor 1 Membrane receptor IC50 8.65 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.10 PDSP
5-hydroxytryptamine receptor 2A GPCR Ki 7.06 PDSP
Alpha-1A adrenergic receptor GPCR WOMBAT-PK
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.96 IUPHAR
D(1B) dopamine receptor GPCR ANTAGONIST Ki 8.10 IUPHAR
Histamine H1 receptor GPCR Ki 9.07 PDSP
D(4) dopamine receptor GPCR Ki 8.80 PDSP
Potassium channel subfamily K member 2 Ion channel IC50 5.70 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.05 CHEMBL
D(1A) dopamine receptor GPCR Ki 7.75 CHEMBL
D(1A) dopamine receptor GPCR IC50 9.52 CHEMBL
Dopamine receptor GPCR IC50 8.52 CHEMBL

External reference:

IDSource
D01044 KEGG_DRUG
2413-38-9 SECONDARY_CAS_RN
C0016367 UMLSCUI
CHEBI:5121 CHEBI
CHEMBL54661 ChEMBL_ID
CHEMBL42055 ChEMBL_ID
DB00875 DRUGBANK_ID
948 IUPHAR_LIGAND_ID
1745 INN_ID
21HMQ851IS UNII
5281881 PUBCHEM_CID
235742 RXNORM
003477 NDDF
003479 NDDF
387567006 SNOMEDCT_US
442075003 SNOMEDCT_US
96220002 SNOMEDCT_US
D005475 MESH_DESCRIPTOR_UI

Pharmaceutical products:

None